Lingzhi(Ganoderma) is widely used in traditional Chinese medicine. Previous studies indicated that Lingzhi was safe, well tolorated, and improved symptoms as an add-on therapy to levodopa in early Parkinson's disease(PD) patients. Here the investigators design a multicenter, randomized, double-blind, placebo-controlled, delayed-start trial to evaluate the effects of Lingzhi on modifying disease progression in untreated PD patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
288
Xuanwu Hospital of Capital Medical University
Beijing, Beijing Municipality, China
RECRUITINGChanges in UPDRS Part III subscores
Compare changes in UPDRS part III scores from baseline to week 72 between early-start group and delayed-start group
Time frame: 72 weeks
Changes in Schwab-England scores
Compare changes in Schwab-England scores from baseline to week 72 between early-start group and delayed-start group
Time frame: 72 weeks
Ratios of subjects in need of additional antiparkinsonian drugs
Compare ratios of subjects in need of additional antiparkinsonian drugs during the 72 week period between early-start group and delayed-start group
Time frame: 72 weeks
Changes in ADAS-COG scores
Compare changes in ADAS-COG scores from baseline to week 72 between early-start group and delayed-start group
Time frame: 72 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.